Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
| Autor: | Guido Bocci, Alfredo Falcone, Lorenzo Fornaro, M. Del Tacca, Romano Danesi, Chiara Cremolini, Gianluca Masi, Giuseppe Pasqualetti, Lisa Salvatore, Fotios Loupakis |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Cancer Research Bevacizumab Colorectal cancer medicine.drug_class VEGF receptors colorectal cancer Angiogenesis Inhibitors Pharmacology Monoclonal antibody Antibodies Monoclonal Humanized chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Drug Discovery Medicine Humans Neoplasm Metastasis Adverse effect VEGF bevacizumab Selection (genetic algorithm) Aged biology Neovascularization Pathologic business.industry Vascular Endothelial Growth Factors Patient Selection Antibodies Monoclonal medicine.disease Vascular endothelial growth factor Regimen chemistry Clinical Trials Phase III as Topic biology.protein business Colorectal Neoplasms medicine.drug |
| Zdroj: | Current Cancer Drug Targets. 999:1-9 |
| ISSN: | 1568-0096 |
| Popis: | Targeting vascular endothelial growth factor (VEGF) pathway represents a successful strategy in the treatment of metastatic colorectal cancer (mCRC). Since the approval of the first antiangiogenic drug, the anti-VEGF monoclonal antibody bevacizumab, a number of other molecules have been tested in preliminary trials and are currently under investigation in phase III randomized studies. At present, no clinical tools are available to select patients more likely to benefit from VEGF pathway inhibitors nor to exclude those who are proner to suffer from specific adverse events, so that almost all mCRC patients are potentially candidate to receive an antiangiogenic-containing regimen. To overcome this substantial limit, a consistent aid is awaited by the identification of molecular tools of selection. Retrospective analyses and translational studies have been conducted and are currently ongoing to address this major question, investigating molecular, biological and genetic markers. This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|